Your 'Time Personality' Is Doing a Number on Your Finances
Sprint Takes On T-Mobile With $60 Unlimited Data Plan
17 Tips for Saving on Back-to-School Shopping
Sony's PS4 Speeds Ahead as Microsoft's XBox Stumbles
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.